Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 13/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 6/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5608392 | 0.92 | CNR1 (0.43) | CNR1ALDH1A1CYP2D6CNR2HPGD | |
| SCHEMBL5390432 | 0.89 | CNR1 (0.64) | CNR1CNR2HPGDSMN1; SMN2HSD17B10 | |
| SCHEMBL4843477 | 0.85 | CNR1 (0.49) | CNR1ALDH1A1CYP2D6CNR2HPGD | |
| SCHEMBL5386529 | 0.84 | CNR1 (0.45) | CNR1CNR2HPGDSMN1; SMN2HSD17B10 | |
| SCHEMBL27647131 | 0.82 | CNR1 (0.39) | CNR1ALDH1A1CNR2HPGDSMN1; SMN2 | |
| SCHEMBL5383708 | 0.82 | CNR1 (0.55) | CNR1CNR2NPC1NPSR1GPR119 | |
| SCHEMBL4836443 | 0.82 | CNR1 (0.43) | CNR1ALDH1A1CYP2D6CNR2 | |
| SCHEMBL5614490 | 0.81 | OPRD1 (0.45) | CNR1ALDH1A1CNR2HPGDSMN1; SMN2 | |
| SCHEMBL27647134 | 0.81 | CNR1 (0.43) | CNR1ALDH1A1CYP2D6CNR2NPC1 | |
| SCHEMBL5685557 | 0.80 | CNR1 (0.40) | CNR1CNR2HPGDSMN1; SMN2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2007502808-A | — | — | 2007-02-15 | — | — | JP | claimed |
| US-7176210-B2 | Cannabinoid receptor ligands and uses thereof | PFIZER INC. (US) | 2007-02-13 | — | — | US | claimed |
| CN-1784243-A | A pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal | PFIZER PROD INC (US) | 2006-06-07 | — | — | CN | claimed |
| EP-1658082-A1 | A PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF ADDICTION IN A MAMMAL | Pfizer Products Inc. (US) | 2006-05-24 | — | — | EP | claimed |
| EP-1626738-A2 | A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF OBESITY OR TO FACILITATE OR PROMOTE WEIGHT LOSS | Pfizer Products Inc. (US) | 2006-02-22 | — | — | EP | claimed |
| EP-1624895-A2 | A PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF NICOTINE ADDICTION IN A MAMMAL | Pfizer Products Inc. (US) | 2006-02-15 | — | — | EP | claimed |
| WO-2005018645-A1 | A PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF ADDICTION IN A MAMMAL | PFIZER PRODUCTS INC. (US) | 2005-03-03 | — | — | WO | claimed |
| US-20050043327-A1 | Pharmaceutical composition for the prevention and treatment of addiction in a mammal | PFIZER INC | 2005-02-24 | — | — | US | claimed |
| WO-2004098580-A2 | A PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF NICOTINE ADDICTION IN A MAMMAL | PFIZER PRODUCTS INC. (US) | 2004-11-18 | — | — | WO | claimed |
| WO-2004098641-A2 | A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF OBESITY OR TO FACILITATE OR PROMOTE WEIGHT LOSS | PFIZER PRODUCTS INC. (US) | 2004-11-18 | — | — | WO | claimed |
| US-20040224963-A1 | Pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal | PFIZER INC | 2004-11-11 | — | — | US | claimed |
| US-20040224962-A1 | Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss | PFIZER INC | 2004-11-11 | — | — | US | claimed |
| US-20040157838-A1 | Cannabinoid receptor ligands and uses thereof | PFIZER INC | 2004-08-12 | — | — | US | claimed |
| US-7176210-B2 | Cannabinoid receptor ligands and uses thereof | PFIZER INC. (US) | 2007-02-13 | — | — | US | disclosed |
| CN-1784243-A | A pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal | PFIZER PROD INC (US) | 2006-06-07 | — | — | CN | disclosed |
| EP-1658082-A1 | A PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF ADDICTION IN A MAMMAL | Pfizer Products Inc. (US) | 2006-05-24 | — | — | EP | disclosed |
| US-20040224963-A1 | Pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal | PFIZER INC | 2004-11-11 | — | — | US | disclosed |
| US-20040224962-A1 | Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss | PFIZER INC | 2004-11-11 | — | — | US | disclosed |
| WO-2004069838-A1 | CANNABINOID RECEPTOR LIGANDS AND USES THEREOF | PFIZER PRODUCTS INC. (US) | 2004-08-19 | — | — | WO | disclosed |
| US-20040157838-A1 | Cannabinoid receptor ligands and uses thereof | PFIZER INC | 2004-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157838-A1 | Cannabinoid receptor ligands and uses thereof | CNR1, CNR2, GPR18 | CNR1 1/4885ALDH1A1 1683/4885CYP2D6 1363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.